Optometry News

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy, to strengthen its clinical-stage pipeline, according to a press release.

OCT angiography alone demonstrated superior sensitivity in detecting glaucomatous changes in the optic disc and macula compared with OCT and OCT angiography combined, according to a study published in Clinical Ophthalmology.

The K8 implant, a first-in-class dual inflammasome inhibitor, demonstrated positive efficacy and safety at 3 months in five patients with bilateral geographic atrophy, according to a press release from Inflammasome Therapeutics.

Stand-alone canaloplasty and trabeculotomy with the Omni surgical system showed positive real-world outcomes in reducing IOP and medication use, according to a study published in American Journal of Ophthalmology.

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release from Sling Therapeutics.

The Paul Glaucoma Implant, a novel glaucoma drainage device, safely and effectively managed uveitic glaucoma in children and adults, according to an analysis of midterm results published in Eye.

Bausch + Lomb launched the enVista Aspire monofocal and toric IOLs in the European Union, according to a press release.

The foveal avascular zone, or FAZ, area deteriorated at 12 months in eyes with stable laser-treated proliferative diabetic retinopathy and macular capillary nonperfusion, but vision loss was not common, according to a study.

Resveratrol supplementation with selective laser trabeculoplasty may be an effective treatment option for glaucoma by reducing IOP and offering neuroprotective benefits, according to a paper published in Open Journal of Ophthalmology.